Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
By I. Edwards HealthDay Reporter
WEDNESDAY, June 18, 2025 — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront.
The deal gives Lilly a potential new treatment for heart disease, The Wall Street Journal reported.
The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal $1.3 billion, The WSJ reported.
Verve’s board has agreed to the sale and recommends that shareholders support the decision. The deal is expected to close by the third quarter of this year.
Verve is developing a new class of gene-editing drugs that could be given just once to treat chronic conditions. Its top drug — Verve-102 — is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.
The treatment is being tested in a Phase 1b clinical trial and has received fast-track designation from the U.S. Food and Drug Administration (FDA), The WSJ added.
“Verve-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,” Ruth Gimeno, Lilly’s vice president of metabolic and diabetes drug development, said.
If the drug passes early trials and moves into a Phase 3 trial, Verve shareholders will receive an additional $3 per share. That payout would happen if the first patient receives the treatment within 10 years of the deal closing.
Verve’s co-founder and CEO, Dr. Sekar Kathiresan, said the company was created with a bold goal: to change how heart disease is treated.
“In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic,” he told The WSJ. “Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly.”
Sources
- The Wall Street Journal, June 17, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Infertility Tied To Heart Problems In Women
WEDNESDAY, June 18, 2025 — Infertility appears linked to women’s risk of heart problems, an evidence review suggests. Women who are infertile have an increased risk...
Blood Pressure Diet Helps Type 2 Diabetics
TUESDAY, June 17, 2025 — A diet meant to lower blood pressure also can be effective in treating type 2 diabetes after a few tweaks, a new clinical trial indicates. The DASH...
Building Strength May Take Less Exercise Than You Think
SATURDAY, June 14, 2025 — Think you need to spend hours lifting weights to build muscle or get stronger? Researchers at Florida Atlantic University say just a few...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.